Esobrick IT 40mg/150mg Capsule is a combination pharmaceutical formulation containing Esomeprazole 40mg and Itopride 150mg, indicated for the management of gastrointestinal disorders characterized by acid-related symptoms and impaired gastric motility. Esomeprazole, a proton pump inhibitor, acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion and promoting ulcer healing. Itopride, a prokinetic agent, enhances gastrointestinal motility by antagonizing dopamine D2 receptors and inhibiting acetylcholinesterase activity, which facilitates gastric emptying and alleviates symptoms of functional dyspepsia such as bloating, nausea, and early satiety. The combined action of Esomeprazole and Itopride provides symptomatic relief in conditions like gastroesophageal reflux disease (GERD), functional dyspepsia, and gastritis, improving patient quality of life. Esobrick IT is generally well tolerated; however, it should be used with caution in patients with known hypersensitivity to either component or in those with severe hepatic or renal impairment. The dosage and duration of therapy should be individualized based on clinical response and patient tolerance. As with all medications, adherence to prescribed guidelines and consultation with a healthcare professional is essential to ensure safety and efficacy.